Ablative stereotactic radiotherapy for oligometastatic colorectal cancer

Systematic review

J. Kobiela, P. Spychalski, G. Marvaso, D. Ciardo, V. Dell'Acqua, F. Kraja, A. Błażyńska-Spychalska, A. J. Łachiński, A. Surgo, R. Glynne-Jones, B. A. Jereczek-Fossa

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Background: SBRT is a novel modality in treatment for oligometastatic colorectal cancer. We aimed to perform a systematic review of results of SBRT in maintaining LC (local control) for CRC liver and lung oligometastases. Materials and methods: The review was performed according to PRISMA and PICO guidelines. Database search using keywords: stereotactic, colon, colorectal, cancer, sbrt, sabr returned 457 results. 15 were included in the study. Only cohorts with CRC histology and reported LC were included. Results: For liver LC rates ranged from 50% to 100% after 1 year and 32% to 91% after 2 years. BED range 40.5–262.5 Gy (Gray). For lung LC rates ranged from 62% to 92% after 1 one year and from 53% to 92% after 2 years. BED range 51.3–262.5 Gy. Conclusions: SBRT of oligometastatic CRC offers high LC with low morbidity and toxicity. It requires more observational studies and randomized trials but available data on clinical efficacy is promising, however not yet matured.

Original languageEnglish
Pages (from-to)91-101
Number of pages11
JournalCritical Reviews in Oncology/Hematology
Volume129
DOIs
Publication statusPublished - Sep 1 2018

Fingerprint

Colorectal Neoplasms
Radiotherapy
Lung
Liver
Colonic Neoplasms
Observational Studies
Histology
Databases
Guidelines
Morbidity
Therapeutics

Keywords

  • Colon cancer
  • Colorectal cancer
  • Oligometastases
  • Rectal cancer
  • SABR
  • SBRT
  • Stereotactic

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Ablative stereotactic radiotherapy for oligometastatic colorectal cancer : Systematic review. / Kobiela, J.; Spychalski, P.; Marvaso, G.; Ciardo, D.; Dell'Acqua, V.; Kraja, F.; Błażyńska-Spychalska, A.; Łachiński, A. J.; Surgo, A.; Glynne-Jones, R.; Jereczek-Fossa, B. A.

In: Critical Reviews in Oncology/Hematology, Vol. 129, 01.09.2018, p. 91-101.

Research output: Contribution to journalReview article

Kobiela, J. ; Spychalski, P. ; Marvaso, G. ; Ciardo, D. ; Dell'Acqua, V. ; Kraja, F. ; Błażyńska-Spychalska, A. ; Łachiński, A. J. ; Surgo, A. ; Glynne-Jones, R. ; Jereczek-Fossa, B. A. / Ablative stereotactic radiotherapy for oligometastatic colorectal cancer : Systematic review. In: Critical Reviews in Oncology/Hematology. 2018 ; Vol. 129. pp. 91-101.
@article{e641701bf308421e9e09b6b42455191b,
title = "Ablative stereotactic radiotherapy for oligometastatic colorectal cancer: Systematic review",
abstract = "Background: SBRT is a novel modality in treatment for oligometastatic colorectal cancer. We aimed to perform a systematic review of results of SBRT in maintaining LC (local control) for CRC liver and lung oligometastases. Materials and methods: The review was performed according to PRISMA and PICO guidelines. Database search using keywords: stereotactic, colon, colorectal, cancer, sbrt, sabr returned 457 results. 15 were included in the study. Only cohorts with CRC histology and reported LC were included. Results: For liver LC rates ranged from 50{\%} to 100{\%} after 1 year and 32{\%} to 91{\%} after 2 years. BED range 40.5–262.5 Gy (Gray). For lung LC rates ranged from 62{\%} to 92{\%} after 1 one year and from 53{\%} to 92{\%} after 2 years. BED range 51.3–262.5 Gy. Conclusions: SBRT of oligometastatic CRC offers high LC with low morbidity and toxicity. It requires more observational studies and randomized trials but available data on clinical efficacy is promising, however not yet matured.",
keywords = "Colon cancer, Colorectal cancer, Oligometastases, Rectal cancer, SABR, SBRT, Stereotactic",
author = "J. Kobiela and P. Spychalski and G. Marvaso and D. Ciardo and V. Dell'Acqua and F. Kraja and A. Błażyńska-Spychalska and Łachiński, {A. J.} and A. Surgo and R. Glynne-Jones and Jereczek-Fossa, {B. A.}",
year = "2018",
month = "9",
day = "1",
doi = "10.1016/j.critrevonc.2018.06.005",
language = "English",
volume = "129",
pages = "91--101",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Ablative stereotactic radiotherapy for oligometastatic colorectal cancer

T2 - Systematic review

AU - Kobiela, J.

AU - Spychalski, P.

AU - Marvaso, G.

AU - Ciardo, D.

AU - Dell'Acqua, V.

AU - Kraja, F.

AU - Błażyńska-Spychalska, A.

AU - Łachiński, A. J.

AU - Surgo, A.

AU - Glynne-Jones, R.

AU - Jereczek-Fossa, B. A.

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Background: SBRT is a novel modality in treatment for oligometastatic colorectal cancer. We aimed to perform a systematic review of results of SBRT in maintaining LC (local control) for CRC liver and lung oligometastases. Materials and methods: The review was performed according to PRISMA and PICO guidelines. Database search using keywords: stereotactic, colon, colorectal, cancer, sbrt, sabr returned 457 results. 15 were included in the study. Only cohorts with CRC histology and reported LC were included. Results: For liver LC rates ranged from 50% to 100% after 1 year and 32% to 91% after 2 years. BED range 40.5–262.5 Gy (Gray). For lung LC rates ranged from 62% to 92% after 1 one year and from 53% to 92% after 2 years. BED range 51.3–262.5 Gy. Conclusions: SBRT of oligometastatic CRC offers high LC with low morbidity and toxicity. It requires more observational studies and randomized trials but available data on clinical efficacy is promising, however not yet matured.

AB - Background: SBRT is a novel modality in treatment for oligometastatic colorectal cancer. We aimed to perform a systematic review of results of SBRT in maintaining LC (local control) for CRC liver and lung oligometastases. Materials and methods: The review was performed according to PRISMA and PICO guidelines. Database search using keywords: stereotactic, colon, colorectal, cancer, sbrt, sabr returned 457 results. 15 were included in the study. Only cohorts with CRC histology and reported LC were included. Results: For liver LC rates ranged from 50% to 100% after 1 year and 32% to 91% after 2 years. BED range 40.5–262.5 Gy (Gray). For lung LC rates ranged from 62% to 92% after 1 one year and from 53% to 92% after 2 years. BED range 51.3–262.5 Gy. Conclusions: SBRT of oligometastatic CRC offers high LC with low morbidity and toxicity. It requires more observational studies and randomized trials but available data on clinical efficacy is promising, however not yet matured.

KW - Colon cancer

KW - Colorectal cancer

KW - Oligometastases

KW - Rectal cancer

KW - SABR

KW - SBRT

KW - Stereotactic

UR - http://www.scopus.com/inward/record.url?scp=85049625349&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049625349&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2018.06.005

DO - 10.1016/j.critrevonc.2018.06.005

M3 - Review article

VL - 129

SP - 91

EP - 101

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

ER -